Simple Summary Prostate cancer affects men of all racial and ethnic groups and leads to
higher rates of mortality in those belonging to a lower socioeconomic status due to late …

Background With continuous progress over the past few decades in understanding
diagnosis, treatment, and genetics, much has been learned about the prostate cancer …

Castration-resistant prostate cancer (CRPC) is a lethal disease, and improvement with
androgen-deprivation therapy has plateaued. Next-generation sequencing studies have led …

Recent genetics and genomics studies of prostate cancer have helped to clarify the genetic
basis of this common but complex disease. Genome-wide studies have detected numerous …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Prostate cancer is one of the most common cancers affecting men with> 1,100,000 new
cases and 300,000 deaths worldwide each year. The disease is more common among older …

Prostate cancers are highly prevalent in the developed world, with inheritable risk
contributing appreciably to tumour development. Genomic heterogeneity within individual …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Objectives Prostate cancer is a prevalent disease with a high impact on patients' morbidity
and mortality. Despite efforts to profile prostate cancer, the genetic alterations and biological …

Prostate cancer is a clinically heterogeneous disease, with some men having indolent
disease that can safely be observed, while others have aggressive, lethal disease. Over the …